Rectal Cancer Clinical Trial
Official title:
A Phase I/II Trial of Proton Therapy With Concurrent Capecitabine for Locally Advanced and Recurrent Rectal Cancer
The primary objective of the Phase I portion of this study is to evaluate the safety of a
combination of capecitabine and proton therapy for patients with locally advanced or
recurrent rectal cancer. The maximum tolerated dose (MTD) will be determined in the Phase I
portion of this trial.
The primary objective of the Phase II portion of this study is to evaluate the local control
rate in patients treated with the above regimen at the MTD.
Secondary Objectives:
1. To evaluate local tumor response in patients treated with the above regimen.
2. To evaluate the relapse-free and overall survival in patients treated with the above
regimen.
3. To evaluate proton dosimetry in patients receiving this treatment.
4. To evaluate quality of life in patients receiving this therapy.
Proton beams can be used to deliver a high dose of radiation to the treatment area while
sparing surrounding normal tissues. Capecitabine is a drug that interferes with the growth
of cancer cells.
Before you can start treatment on this study, you will have what are called "screening
tests." These tests will help the doctor decide if you are eligible to take part in this
study. You will have a complete physical exam. Blood (about 2 tablespoons) will be drawn for
routine tests. Urine will be collected for routine tests. Chest x-rays and computed
tomography (CT) scans of the abdomen (stomach area) and pelvis will be done. Women who are
able to have children must have a negative blood or urine pregnancy test.
If you are found to be eligible to take part in this study, you will receive radiation
therapy 1 time a day, for 5 days in a row (Monday-Friday) for 6 -7 weeks (30-35 treatments
in all). You will take the chemotherapy drug, capecitabine, by mouth 2 times a day, at
morning and night, on each of the days that you receive radiation therapy. These pills will
not be taken on Saturday or Sunday. These pills should be taken within 30 minutes of eating
and with a full glass of water.
During the study, every week you will have a physical exam and blood (about 2 teaspoons)
will be drawn to check for side effects from chemotherapy and radiation therapy. You will be
asked about any side effects you are experiencing.
You will be evaluated by a surgeon 4-6 weeks after the completion of treatment. Those with
tumors that can be surgically removed will have surgery to remove the tumor 6-8 weeks after
completion of treatment, as they would for the standard of care for their disease.
You will be taken off study if the disease gets worse or intolerable side effects occur.
Two (2) weeks after completing radiation therapy, you will have a follow-up visit. At this
visit, you will have a physical exam. Blood (about 2 teaspoons) will be collected for
routine tests. You will be asked about any side effects you are experiencing. Six (6) weeks
after completing radiation therapy, you will have a follow-up visit. At this visit, you will
have a physical exam, chest x-ray, and CT scan of your abdomen and pelvis. Blood (about 2
teaspoons) and urine will be collected for routine tests. You will be asked about any side
effects you are experiencing.
After finishing treatment, you will have a follow-up visit every 3 months for the first 2
years, and every 6 months after that. At each visit, you will have a physical exam. Blood
(about 2 teaspoons) and urine will be collected for routine tests. You will have a chest
x-ray and CT scan of the abdomen and pelvis. You will be asked about any side effects you
are experiencing.
One (1) year after you finish treatment, you will also have a colonoscopy or sigmoidoscopy.
You will receive a separate consent for these procedures.
After participation in the study is over, you will have follow-up evaluation as needed for
standard of care.
This is an investigational study. Capecitabine is FDA approved for treating colon cancer
after surgery, and for treating metastatic colorectal cancer. The use of capecitabine with
proton beam therapy in this study is investigational. About 50 patients will take part in
this study. All will be enrolled at M. D. Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
| Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
| Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
| Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
| Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
| Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
| Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
| Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
| Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
| Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
| Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
| Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
| Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
| Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 |